Study of Novel Treatment Combinations in Patients With Lung Cancer

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of

Trial Details

NCT ID
NCT05633667
Phase
PHASE2
Sponsor
Gilead Sciences
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Zimberelimab (ZIM)
  • Domvanalimab (DOM)
  • Sacituzumab govitecan-hziy (SG)
  • Etrumadenant (ETRUMA)
  • Carboplatin
  • Cisplatin
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Fort Wayne, Indiana, United States|41.1306,-85.12886

Key Eligibility Criteria

  • All Substudies:
  • Histologically or cytologically documented non-small-cell lung cancer (NSCLC).
  • No known actionable genomic alterations for which targeted therapies are available.
  • Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →